A novel three-dimensional stromal-based model forin vitrochemotherapy sensitivity testing of leukemia cells
- 15 May 2013
- journal article
- research article
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 55 (2), 378-391
- https://doi.org/10.3109/10428194.2013.793323
Abstract
The disparate response of leukemia cells to chemotherapy in vivo, compared to in vitro, is partly related to the interaction of leukemic cells and the three-dimensional bone marrow stromal microenvironment. We investigated the effects of chemotherapy agents on leukemic cell lines co-cultured with human bone marrow mesenchymal stem cells (hu-BM-MSCs) in a three-dimensional model (3D). Comparison was made to leukemic cells treated in suspension, or grown on a hu-BM-MSC monolayer (2D conditions). We demonstrated that leukemic cells cultured in 3D were more resistant to drug-induced apoptosis compared to cells cultured in 2D or in suspension. We also demonstrated significant differences in leukemic cell response to chemotherapy using different leukemic cell lines cultured in 3D. We suggest that the differential responses to chemotherapy in 3D may be related to the expression of N-cadherin in the co-culture system. This unique model provides an opportunity to study leukemic cell responses to chemotherapy in 3D.This publication has 34 references indexed in Scilit:
- A phase 1 dose‐escalation study of ARRY‐520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemiasCancer, 2011
- p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α–mediated down-regulation of CXCL12Blood, 2011
- Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamicsCancer Management and Research, 2011
- Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamicsCancer Management and Research, 2011
- Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemiaInvestigational New Drugs, 2011
- Further activation of FLT3 mutants by FLT3 ligandOncogene, 2011
- Ectopic Human Mesenchymal Stem Cell-Coated Scaffolds in NOD/SCID Mice: An In Vivo Model of the Leukemia NicheTissue Engineering, Part C: Methods, 2010
- N-Cadherin Expression Level Distinguishes Reserved versus Primed States of Hematopoietic Stem CellsCell Stem Cell, 2008
- Identification of the haematopoietic stem cell niche and control of the niche sizeNature, 2003
- Established leukemia cell lines: Their role in the understanding and control of leukemia proliferationCritical Reviews in Oncology/Hematology, 1985